戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1   The majority of donor recipient pairs were HLA mismatched (4.6+/-1.2 of the six major HLA antigens)
2         Fifty-two donor/recipient pairs were HLA-mismatched, 41 at HLA-A and -B and 11 at HLA-DR and
3 ithout significant suppression of completely HLA-mismatched, Ag-induced proliferation.
4 g beads containing the corresponding donor's HLA-mismatched Ags.
5 ; n = 577) as well as to patients undergoing HLA-mismatched allo HCT.
6                     Human leukocyte antigen (HLA)-mismatched allogeneic hematopoietic stem cell trans
7 rom those mediating GVL in each of the eight HLA-mismatched and one HLA-matched donor/recipient pairs
8 CT recipients, including 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of m
9 d T-replete grafts, 97% received marrow, 95% HLA-mismatched, and 97% received calcineurin-based graft
10 mulator used for priming, but not on control HLA-mismatched APC.
11 merism can be induced in adult recipients of HLA-mismatched bone-marrow transplantation by a non-myel
12 aft survival for 7614 HLA-matched and 81,364 HLA-mismatched cadaveric kidney transplantations reporte
13 rvous system of a child who had undergone an HLA-mismatched cadaveric lung transplant.
14                    719 recipients of primary HLA-mismatched cadaveric or living-donor renal allograft
15          A similar effect was observed among HLA-mismatched cases (28%, 22%, and 19%, respectively).
16 hanisms for this, we compared the ability of HLA-mismatched CB and adult peripheral blood (PB) T cell
17 tologous DC, Mtb-infected autologous DC, and HLA-mismatched CD1+ targets (DC), as well as HLA-mismatc
18 HLA-mismatched CD1+ targets (DC), as well as HLA-mismatched CD1- targets (macrophages).
19 achieve the same degree of HIV inhibition as HLA-mismatched CD8(+) T cells.
20 LA-matched set and relapse (P < .001) in the HLA-mismatched cohort.
21                                              HLA-mismatched cord blood should be considered an accept
22       Simulations using 46 ICPs and 11 fully HLA-mismatched CPs were undertaken using the Australian
23 ing KIR ligand' might not be limited only to HLA mismatched donor-recipient combinations but may be a
24 sed risk of sclerosis included the use of an HLA-mismatched donor and a major ABO-mismatched donor.
25 nosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and
26                                              HLA-mismatched donor bone-marrow transplantation after s
27                          Alloanergization of HLA-mismatched donor T cells efficiently and selectively
28 -reactive T cell repertoire for any specific HLA-mismatched donor-recipient pair.
29 hematopoietic stem-cell transplantation with HLA mismatched donors.
30        HSCs from 2 human lymphocyte antigen (HLA)-mismatched donors were injected individually or sim
31  patients who received transplantations from HLA-mismatched donors (39.5% +/- 10.4%, P <.05) or HLA-m
32       The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients
33                                     Although HLA-mismatched donors can mount high-avidity CTLs agains
34 ografts and/or transplants from unrelated or HLA-mismatched donors seem to be predominantly affected.
35  suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protoc
36 ation of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropria
37           Fifty-seven HLA-matched donors, 12 HLA-mismatched donors, and 1 CD3(+)TCR alphabeta/CD19 de
38 ng bone marrow transplants from unrelated or HLA-mismatched donors.
39 or patients with end-stage renal disease and HLA-mismatched donors.
40 ed EBV-specific CTL to autologous but not to HLA-mismatched EBV+ tumors as early as 24 h after intrav
41 traperitoneally with autologous but not with HLA-mismatched EBV-LCL had significantly improved surviv
42  with grafts that were HLA-matched (n=35) or HLA-mismatched for one (n=201) or two antigens (n=267) (
43 uiescence (operational tolerance) against an HLA-mismatched graft, allowing them to withdraw all immu
44 ymocyte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch).
45  allografts increases the risk of failure of HLA-mismatched grafts during the first year after transp
46 disease, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazar
47  associations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60
48 azard ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30
49 in the cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02
50 n of multiple viruses included cord blood or HLA-mismatched HCT, myeloablative conditioning, and acut
51                                          KIR/HLA mismatched hematopoietic stem cell transplants induc
52 o being applied to permit transplantation of HLA mismatched hematopoietic stem cells to patients with
53 ) transgenic mice and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT),
54 titution while limiting alloreactivity after HLA-mismatched hematopoietic stem cell transplantation,
55  developed a single human leukocyte antigen (HLA)-mismatched heterotopic murine heart transplant mode
56 -CD25 immunotoxin following stimulation with HLA-mismatched host LCLs more consistently depleted in v
57  capacity may enable their persistence in an HLA-mismatched host.
58 s in HIV-1 that persist upon transmission to HLA-mismatched hosts may spread in the population as the
59                                           In HLA-mismatched HSCT, alloreactivity occurs when licensed
60 ic viral infections underwent an allogeneic, HLA-mismatched HSCT.
61 tion, SCID-hu mice were transplanted with an HLA-mismatched human fetal pancreas.
62 s from two patients were cotransplanted with HLA-mismatched human islets into immunodeficient mice.
63 lls) was alloantigen-specific expanded using HLA-mismatched immature, mature monocyte-derived dendrit
64 GVHD had marrow donors who were unrelated or HLA-mismatched in 27/63 cases.
65 gical rejection of Human Leukocyte Antigens (HLA)-mismatched induced pluripotent stem cells (iPSCs) l
66                  After March 1995, 1067 zero HLA-mismatched kidneys that were not phenotypically iden
67   However, the 5-year graft survival rate in HLA-mismatched kidneys without DGF was significantly hig
68 d kidneys, and most recently to sharing zero HLA-mismatched kidneys.
69 cadaver kidneys is justifiable only for zero-HLA-mismatched kidneys.
70 ly higher killing of autologous LCLs than of HLA-mismatched LCLs (mean, 56% vs. 14% at 20:1 ratio).
71 31, p=0.0003) and possibly after one-antigen HLA-mismatched low-cell-dose umbilical-cord-blood transp
72 100(+) HLA-matched melanoma targets, but not HLA-mismatched melanoma or gp100(-) nonmelanoma tumor li
73 ture of the same target cells with activated HLA-mismatched mitogen-activated lymphomononuclear cells
74 isotype-matched control antibody were fed to HLA-mismatched monocyte-derived immature DCs.
75                         We treated mice with HLA-mismatched mouse cardiac transplant with atorvastati
76                     They did not lyse either HLA-mismatched, MYCN-amplified, or matched/nonmatched, n
77 n followed by donor-recipient inhibitory KIR-HLA mismatched NK cells is well tolerated by patients an
78 n-like receptor-human leukocyte antigen (KIR-HLA) mismatched NK cells (median, 29 x 10(6)/kg NK cells
79 bearing both the autologous and either fully HLA-mismatched or genotypically related haplotype-sharin
80    Transplantation using T-cell depletion or HLA-mismatched or umbilical cord donors was also exclude
81                       Donors were unrelated, HLA mismatched, or both in 59% of patients.
82 patients, partially human leukocyte antigen (HLA)-mismatched, or HLA-haploidentical, related donor bo
83                                       In 141 HLA-mismatched pairs, 28% were matched for DPB1.
84 %) in matched and 32% (95% CI, 8% to 52%) in HLA-mismatched patients (P = .57).
85                           Bortezomib-treated HLA-mismatched patients experienced rates of NRM, acute
86 aluable patients in group 2, the regimen for HLA-mismatched patients was changed in 1984 to include C
87                                         With HLA-mismatched peripheral blood mononuclear cell (PBMC)
88                                              HLA-mismatched placental blood from unrelated donors is
89 y results of transplantation using partially HLA-mismatched placental blood from unrelated donors.
90 HLA-matched family donors are available, but HLA-mismatched procedures are associated with substantia
91 and compared with those against equivalently HLA mismatched recipient:third-party controls.
92 A-matched recipient and the other went to an HLA-mismatched recipient.
93                Four human leukocyte antigen (HLA)-mismatched recipients of living donor kidney transp
94 ed risk of rejection over the first year for HLA-mismatched recipients (0.87, P<0.001).
95        No grades 3 to 4 aGVHD occurred in 11 HLA-mismatched recipients in the 1.5 mg/m(2) group.
96 crochimerism can be achieved without GVHD in HLA-mismatched recipients of combined kidney and hematop
97 llow-up in a phase IIb tolerance protocol in HLA-mismatched recipients of living donor kidney plus fa
98 l value of CREG matching observed in the one-HLA-mismatched recipients of the UNOS (but not the Pitts
99 ) with unrelated or human leukocyte antigen (HLA) mismatched related donor (relative risk [RR] = 4.1)
100  from unrelated and human leukocyte antigen (HLA)-mismatched related donors.
101  allografting using human leukocyte antigen (HLA)-mismatched related donors.
102 l-depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lym
103 -cell-depleted transplants from unrelated or HLA-mismatched related donors from 1982 to 1994.
104  HLA-matched alloBMT and increase the use of HLA-mismatched related donors.
105  There were no differences in survival after HLA-mismatched related, HLA-matched unrelated, or mismat
106     Thirty-one patients received marrow from HLA-mismatched relatives who differed by one or more loc
107 d grafts from HLA-matched siblings, 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41%
108 571 unique peripheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontr
109 ng cell line HTC 9062 were used to stimulate HLA-mismatched responder cells from 8 individuals.
110                                   The triple HLA-mismatched SCID-hu model represents a novel in vivo
111 0), suggesting that the allograft of Class I HLA-mismatched seropositive donors is inaccessible to CD
112  high risk of GVHD, infection, or both in an HLA-mismatched setting.
113 -HLA polymorphisms in the unrelated HSCT and HLA-mismatched setting.
114            In 47 recipients of unrelated and HLA-mismatched stem cells, mortality at transplantation
115 argets sharing HLA class I antigens, but not HLA mismatched targets.
116 cific T cells can have cross-reactivity with HLA-mismatched targets in vitro.
117 ll receptors (TCRs) isolated from allogeneic HLA-mismatched TCR repertoires has, however, been impede
118 us EBV+ tumors, one autologous and the other HLA mismatched to the EBV-specific CTL donor, had regres
119  human histocompatibility leukocyte antigen (HLA)-mismatched, transformed, B lymphocyte cell lines (L
120 ficial for control of GVHD in T-cell-replete HLA-mismatched transplantation.
121 or treatment of patients with leukemia after HLA-mismatched transplantation.
122 evance for predicting HSCT outcome, even for HLA mismatched transplants.
123 transplants, as compared with 37 percent for HLA-mismatched transplants.
124 tively, for HLA-matched transplants than for HLA-mismatched transplants.
125 s' restricting HLA allele but not in EBV- or HLA-mismatched tumors.
126 ecipients of 0 to 3 human leukocyte antigen (HLA)-mismatched UCB and HLA-A, B, DRB1-matched BM was pe
127 tched unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007).
128 been observed in leukemia patients receiving HLA-mismatched umbilical cord (UCB) transplants.
129 were higher after transplants of two-antigen HLA-mismatched umbilical cord blood (relative risk 2.31,
130 e use of HLA-matched and one- or two-antigen HLA-mismatched umbilical cord blood in children with acu
131 tal-body irradiation and then transplants of HLA-mismatched umbilical-cord blood.
132   Relapse rates were lower after two-antigen HLA-mismatched umbilical-cord-blood transplants (0.54, p
133 or cord blood transplantation from partially HLA-mismatched units can cure many children with leukemi
134 ling (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated (n = 3), and HLA haploidentical
135  an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98).
136                                              HLA-mismatched unrelated donor (MMUD) hematopoietic stem
137       Life-threatening risks associated with HLA-mismatched unrelated donor hematopoietic cell transp
138                                Outcome after HLA-mismatched unrelated donor transplantation is influe
139 s) undergoing transplantation with partially HLA-mismatched unrelated donor umbilical cord blood were
140 bility after receipt of a transplant from an HLA-mismatched unrelated donor.
141 ymorphisms (SNPs) in 2628 patients and their HLA-mismatched unrelated donors to determine whether SNP
142 elatives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donors.
143 d CML CFU-GM comparably to effectors from 14 HLA-mismatched unrelated individuals (mean inhibition 42
144 hypothesis that removal of CD4 cells from an HLA-mismatched unrelated marrow graft would substantiall
145 cate that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vit
146  transplants where donors and recipients are HLA mismatched, we distinguish between donor liver-deriv

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top